Fritz Frye, PA
Payments from drug & device makers
Across 154 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$914
- Phathom Pharmaceuticals, Inc.$354
- Novo Nordisk$335
- GSK$222
- AbbVie$216
- Lilly USA, LLC$197
- plus $812 from 16 others
What the payments were for
- Food & beverage$3,050100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 48 | $914 |
| Phathom Pharmaceuticals, Inc. | 8 | $354 |
| Novo Nordisk | 18 | $335 |
| GSK | 13 | $222 |
| AbbVie | 12 | $216 |
| Lilly USA, LLC | 13 | $197 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $164 |
| Supernus Pharmaceuticals, Inc. | 3 | $128 |
| Bayer | 5 | $81 |
| Amarin Pharma, Inc. | 4 | $77 |
| Boehringer Ingelheim | 2 | $50 |
| Sanofi-aventis U.S. LLC | 2 | $44 |
| Amgen(2 entities) | 3 | $43 |
| Pfizer | 3 | $43 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Johnson & Johnson | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Vivus LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$135
How this compares
$3,050 in reported general payments places this provider in the 75th percentile of 384 medical providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 123 | $145,927 |
| MounjaroTirzepatide | 109 | $145,760 |
| FarxigaDapagliflozin Propanediol | 164 | $125,871 |
| EliquisApixaban | 72 | $69,167 |
| TrulicityDulaglutide | 33 | $46,809 |
| XareltoRivaroxaban | 57 | $43,829 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $37,963 |
| JardianceEmpagliflozin | 39 | $30,123 |
| JanuviaSitagliptin Phosphate | 43 | $29,173 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $17,299 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $16,790 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $11,820 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $10,292 |
| MyrbetriqMirabegron | 12 | $9,159 |
| LinzessLinaclotide | 16 | $8,369 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $197 | $192,569142 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $914 | $148,937211 claims |
| Novo NordiskOzempic | $335 | $145,927123 claims |
| PfizerEliquis, Premarin | $43 | $76,798103 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $222 | $48,25568 claims |
| Johnson & JohnsonXarelto | $33 | $43,82957 claims |
| Boehringer IngelheimJardiance | $50 | $30,12339 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $44 | $11,82014 claims |
| AbbVieLinzess, Synthroid | $216 | $10,88678 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 384 medical providers in South Carolina.
Other medical in Aynor
- Christopher ThompsonSpartanburg$78K
- Laura BuchGreenville$73K
- Suzanne SmithWest Columbia$39K
- Stavros ChrysostomidesColumbia$39K
- Ethan CaseySpartanburg$24K
- Jessica HallColumbia$22K
- Mary MacdonaldCharleston$20K
- Cameron PappasGreenville$18K
- Leslie RumbautGrenville$18K
- Claire DukeGreenville$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.